Susquehanna International Group, LLP Altimmune, Inc. Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

A detailed history of Susquehanna International Group, LLP transactions in Altimmune, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 2,210,401 shares of ALT stock, worth $17.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,210,401

Previous 916,254 141.24%

Holding current value

$17.4 Million

Previous $9.33 Million 57.6%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$5.91 - $10.23 $7.65 Million - $13.2 Million	1,294,147 Added 141.24%	2,210,401 $14.7 Million
Q1 2024 May 07, 2024	BUY	$8.22 - $13.81 $1.5 Million - $2.53 Million	183,000 Added 24.96%	916,254 $9.33 Million
Q4 2023 Feb 14, 2024	BUY	$2.14 - $11.62 $1.33 Million - $7.2 Million	619,488 Added 544.53%	733,254 $8.25 Million
Q3 2023 Nov 14, 2023	SELL	$2.4 - $3.45 $156,604 - $225,119	-65,252 Reduced 36.45%	113,766 $295,000
Q2 2023 Aug 11, 2023	SELL	$3.45 - $5.97 $2.13 Million - $3.69 Million	-617,704 Reduced 77.53%	179,018 $631,000
Q1 2023 May 16, 2023	BUY	$4.19 - $16.83 $1.86 Million - $7.48 Million	444,649 Added 126.29%	796,722 $3.36 Million
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $1.55 Million - $2.91 Million	176,786 Added 100.86%	352,073 $5.79 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $1.87 Million - $3.93 Million	175,287 New	175,287 $2.24 Million
Q1 2022 May 16, 2022	SELL	$5.9 - $9.45 $67,448 - $108,032	-11,432 Reduced 8.37%	125,219 $763,000
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $444,702 - $638,651	51,174 Added 59.87%	136,651 $1.25 Million
Q3 2021 Nov 15, 2021	SELL	$8.43 - $16.81 $624,873 - $1.25 Million	-74,125 Reduced 46.44%	85,477 $967,000
Q2 2021 Aug 11, 2021	SELL	$9.85 - $16.46 $1.67 Million - $2.79 Million	-169,382 Reduced 51.49%	159,602 $1.57 Million
Q1 2021 May 17, 2021	BUY	$12.71 - $24.31 $56,966 - $108,957	4,482 Added 1.38%	328,984 $4.65 Million
Q4 2020 Feb 16, 2021	BUY	$7.84 - $14.22 $1.68 Million - $3.05 Million	214,753 Added 195.68%	324,502 $3.66 Million
Q3 2020 Nov 16, 2020	BUY	$9.93 - $33.26 $911,305 - $3.05 Million	91,773 Added 510.53%	109,749 $1.45 Million
Q4 2019 Feb 14, 2020	SELL	$1.53 - $2.15 $3,935 - $5,529	-2,572 Reduced 12.52%	17,976 $34,000
Q3 2019 Nov 14, 2019	SELL	$1.95 - $2.66 $54,835 - $74,801	-28,121 Reduced 57.78%	20,548 $40,000
Q2 2019 Aug 16, 2019	BUY	$2.19 - $3.4 $440 - $683	201 Added 0.41%	48,669 $116,000
Q2 2019 Aug 14, 2019	SELL	$2.19 - $3.4 $19,911 - $30,912	-9,092 Reduced 15.8%	48,468 $115,000
Q1 2019 May 15, 2019	BUY	$2.54 - $4.54 $146,202 - $261,322	57,560 New	57,560 $167,000

Others Institutions Holding ALT

# of Institutions

191

Shares Held

42.4M

Call Options Held

1.05M

Put Options Held

582K

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $386M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Altimmune, Inc. Transaction History